Relationship between drug use and motor function after subthalamic deep brain stimulation

• Published in: Neurological Therapeutics Vol. 39; no. 5; pp. 808 - 812
• Main Authors: Kajikawa, Hiroyuki, Tomimoto, Hidekazu, Matsuura, Keita, Utsunomiya, Takaya, Araki, Tomohiro, Matsuyama, Hirofumi
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Neurological Therapeutics 2022; 日本神経治療学会
• Subjects: deep brain stimulation; MAO–B inhibitors; medication; Parkinson's disese
• ISSN: 0916-8443; 2189-7824
• DOI: 10.15082/jsnt.39.5_808

Purpose. No fixed method has been established for postoperative drug use in deep brain stimulation (DBS) therapy for Parkinson's disease (PD). This study aims to examine the relationship between drug use and prognosis after 1 year of treatment and to optimize postoperative drug therapy. Method. The relationship between drug use and motor function changes was examined after 1 year of treatment. Result. The mean age and disease duration were 62.7 years and 13.4 years, respectively. The mean L–dopa and L–dopa equivalent daily doses were 470 and 897mg, respectively. A significant difference in the Movement Disorder Society–Sponsored Revision of the Unified Parkinson's Disease Rating Scale part III improvement rate was observed when examined with and without monoamine oxidase type B (MAO–B) inhibitors (9 with MAO–B inhibitors (selegiline 5 and rasagiline 4) and 14 without MAO–B inhibitors) at 1 year (77 vs. 35%, p＝0.012). Conclusion. Concomitant use of MAO–B inhibitors may improve the off status after the DBS of the subthalamic nucleus in PD.